11 unknown, 8 completed, 6 recruiting, 4 terminated. 35 Phase 1, 14 Phase 2.
Follow Cell- and Tissue-Based Therapy: new trials by email Literature Review of Cell- and Tissue-Based Therapy trials Research Report on Cell- and Tissue-Based Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia APR-2020 - RPS19 Deficient Diamond-Blackfan Anemia | Phase 1 | Recruiting | Apriligen, Inc. | 4 | 2026-04-16 | 2026-07-21 |
| Autologous CAR-T Cells Targeting B7-H3 in PDAC iC9-CAR.B7-H3 T cell infusion - Pancreas Cancer, Relapse | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 27 | 2024-07-18 | 2026-06-08 |
| A Clinical Study to Evaluate CUD005 Injection in Patients with Liver Cirrhosis Cell therapy - Cirrhosis Liver | Phase 1 | Enrolling by invitation | Anhui Provincial Hospital | 9 | 2024-06-21 | 2024-11-04 |
| GPC3/Mesothelin-CAR-γδT Cells Against Cancers Cell therapy for solid tumors - Pancreas Cancer, Lung Cancer | Phase 1 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 30 | 2024-05-10 | 2024-06-26 |
| Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC Cyclophosphamide, Fludarabine, Cell Therapy - Head and Neck Cancer, Relapse | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 33 | 2024-04-05 | 2026-09-16 |
| A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma AZD5851 - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 94 | 2023-12-14 | 2026-08-19 |
| To Evaluate the Clinical Study of CUD005 Injection in Patients With Cirrhosis Cell therapy - Cirrhosis, Liver | Phase 1 | Unknown | Anhui Provincial Hospital | 9 | 2023-08-09 | 2024-03-06 |
| Using T-Cell Alloreactivity and Chimerism to Guide Immunosuppression Minimization in Intestinal Transplantation Cell Therapy - Intestinal Transplantation | Phase 1 | Recruiting | Columbia University | 6 | 2021-10-22 | 2026-04-01 |
| Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients with a First Clinical Episode Highly Suggestive of Multiple Sclerosis Cellular therapy with EBV specific autologous CTL infusion - Multiple Sclerosis | Phase 1 | Recruiting | Nantes University Hospital | 7 | 2021-01-26 | 2025-02-19 |
| Open-label Phase I Study for PEP or Treatment of HS-ARS PLX-R18 for the Post-Exposure Prevention (PEP) or Treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS) Cell therapy - Ionizing Radiation Exposure | Phase 1 | Unknown | Pluristem Ltd. | 27 | 2021-01-01 | 2020-07-28 |
| Mesenchymal Stem Cells (MSCs) - Like Cell Transplantation in Women With Primary Ovarian Insufficiency Cell therapy - Primary Ovarian Insufficiency | Phase 1 | Unknown | Chinese Academy of Sciences | 28 | 2019-04-03 | 2021-08-05 |
| Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Aldesleukin, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cellular Therapy - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 4 | 2019-03-08 | 2024-09-19 |
| Bone Marrow Mononuclear Cells vs Mesenchymal Stem Cells in Diabetic Patients With Chronic Limb Ischemia Cell-based therapy - Chronic Limb-threatening Ischemia, Diabetes Mellitus | Phase 1 / Phase 2 | Completed | Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle | 24 | 2019-01-01 | 2022-11-30 |
| TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma 18F-FHBG, Aldesleukin, Cellular Therapy - HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2018-07-10 | 2020-07-24 | |
| Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease Cellavita HD Lower Dose, Cellavita HD Higher dose - Huntington Disease | Phase 1 | Unknown | Azidus Brasil | 6 | 2017-10-16 | 2022-11-02 |
| Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer 18F-FHBG, Aldesleukin, Busulfan - HLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 5 | 2017-07-26 | 2023-11-01 |
| Mesenchymal Stromal Cell Derivatives in the Treatment of Chronic Diabetic Foot Ulcers Type 1 and 2 dac-MSCs, MSCs, Fitostimoline - Foot Ulcer, Diabetic | Phase 1 / Phase 2 | Unknown | Universidad Autónoma de Bucaramanga | 51 | 2017-01-01 | 2016-10-24 |
| Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss Autologous Bone Marrow Infusion - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Suspended | James Baumgartner, MD | 10 | 2015-10-01 | 2022-03-18 |
| Allogeneic Adipose Derived Stem Cells for Werdnig Hoffman Patients Adipose derived mesenchymal stem cell - Infantile Spinal Muscular Atrophy, Type I [Werdnig- Hoffman] | Phase 1 / Phase 2 | Unknown | Tehran University of Medical Sciences | 10 | 2015-06-01 | 2016-08-04 |
| Allogenic Bone Marrow Derived Mesenchymal Stem Cell Therapy in Cases of Hemophilia Cellular therapy, cellular therapy - Hemophilia | Phase 1 | Unknown | Cairo University | 20 | 2014-08-01 | 2014-04-09 |
Showing 20 of 35. Sign in to see all of them.
Chronic Limb-Threatening Ischemia (2) · Diabetes Mellitus (2) · Fibrosis (2) · Hearing Loss, Sensorineural (2) · Liver Neoplasms (2) · Neoplasms (2) · Pancreatic Neoplasms (2) · Recurrence (2) · Adenoviridae Infections (1) · Anemia, Diamond-Blackfan (1) · Callosities (1) · Carcinoma, Hepatocellular (1) · Coronary Artery Disease (1) · Cytomegalovirus Infections (1) · Diabetic Foot (1)
Assistance Publique - Hôpitaux de Paris (3) · Anhui Provincial Hospital (2) · James Baumgartner, MD (2) · Jonsson Comprehensive Cancer Center (2) · UNC Lineberger Comprehensive Cancer Center (2) · Air Force Military Medical University, China (1) · Apriligen, Inc. (1) · AstraZeneca (1) · Azidus Brasil (1) · Azienda Unita Sanitaria Locale di Piacenza (1) · Cairo University (1) · Centre Hospitalier Universitaire de Nice (1) · Chinese Academy of Sciences (1) · Columbia University (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1)
United States (11) · France (7) · China (5) · Iran (2) · Italy (2) · Brazil (1) · Colombia (1) · Egypt (1) · Japan (1) · Russia (1) · South Korea (1) · Spain (1) · Switzerland (1)
James Baumgartner, MD (2) · Amir Ali Hamidieh, MD (1) · Ashwin Somasundaram, MD (1) · Attilio Odero, Professor (1) · Claudia L Sossa-Melo, MD (1) · Emese Zsiros, MD (1) · Eugenio Fernandez, MD (1) · Hamid Gourabi, PhD (1) · Hongmei Wang, Doctor (1) · Jared Weiss, MD (1) · Joseph Emmerich (1) · Joyce Macedo da Silva, MD (1) · Lianxin LX Liu, Professor (1)
PMID 21148423, PMID 21986637, PMID 22040109, PMID 24105925, PMID 25974235, PMID 26439886, PMID 26526721, PMID 26895633, PMID 27246524, PMID 28753830, PMID 37626416, PMID 40593578, PMID 41188963, PMID 42265522
R01CA296807 (1)